Wilms tumor protein 1 (WT1) peptide-HLA complex (WT1-HLA)

Wilms tumor protein 1 (WT1) is a zinc-finger transcription factor that plays a vital role in the development of the urogenital system but is pathologically overexpressed in many leukemias and solid tumors (UniProt: P19544). Because WT1 is an intracellular protein, it cannot be targeted by traditional antibody therapies; instead, it is processed into peptide fragments that are presented on the cell surface by Human Leukocyte Antigen (HLA) molecules (PubMed: 17460054). This peptide-HLA complex serves as a highly specific tumor-associated antigen (TAA) that can be recognized by the cellular immune system. Modern immunotherapeutic strategies, such as the Galinpepimut-S vaccine and TCR-engineered T-cell therapies, are designed to target this complex to induce a potent cytotoxic T-lymphocyte response against cancer cells (NIH: National Cancer Institute). These treatments are currently being evaluated for their efficacy in diseases like acute myeloid leukemia and mesothelioma, where WT1 is a known oncogenic driver. The clinical application of these therapies requires precise HLA matching and careful monitoring for potential off-target effects in tissues where WT1 is physiologically expressed, such as the kidneys (Journal of Hematology & Oncology, 2021).

Other names

WT1-MHC complexWT1-derived peptide-HLA complexWilms tumor 1 antigenWT1-HLA-A*02:01Wilms tumor protein 1 epitope

Therapeutic agents target the specific complex formed by WT1-derived peptides and HLA molecules on the cell surface. Recognition by T-cell receptors (TCRs) or TCR-mimetic molecules triggers a cytotoxic immune response, primarily through CD8+ T-cell activation, leading to the selective lysis of WT1-expressing malignant cells (PubMed: 17460054, Journal of Hematology & Oncology, 2021).